Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience

Balash, Yacov; Schleider, Lihi Bar-Lev; Korczyn, Amos D.; Shabtai, H.; Knaani, Judith; Rosenberg, Alina; Baruch, Yehuda; Djaldetti, Ruth; Giladi, Nir; Gurevich, Tanya

doi:10.1097/wnf.0000000000000246

Cited by 63 publications

(57 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a different study reported that the main benefit was observed in sleep rather than in motor symptoms [174]. A retrospective study collecting subjective impressions of patients with PD under medical cannabis suggests an improvement in the initial stages of treatment without major adverse effects [175]. The different outcome of studies using plant extracts could be related to the administration route because cannabinoids are lipid-soluble compounds; hence, oral administration results in lower peak concentrations in plasma than through inhalation.…”

Section: Clinical Evidence For the Therapeutic Potential Of Cannabinomentioning

confidence: 99%

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Aymerich

Aso

Abellanas

et al. 2018

Biochemical Pharmacology

View full text Add to dashboard Cite

The endocannabinoid system (ECS) exerts a modulatory effect of important functions such as neurotransmission, glial activation, oxidative stress, or protein homeostasis. Dysregulation of these cellular processes is a common neuropathological hallmark in aging and in neurodegenerative diseases of the central nervous system (CNS). The broad spectrum of actions of cannabinoids allows targeting different aspects of these multifactorial diseases. In this review, we examine the therapeutic potential of the ECS for the treatment of chronic neurodegenerative diseases of the CNS focusing on Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. First, we describe the localization of the molecular components of the ECS and how they are altered under neurodegenerative conditions, either contributing to or protecting cells from degeneration. Second, we address recent advances in the modulation of the ECS using experimental models through different strategies including the direct targeting of cannabinoid receptors with agonists or antagonists, increasing the endocannabinoid tone by the inhibition of endocannabinoid hydrolysis, and activation of cannabinoid receptor-independent effects. Preclinical evidence indicates that cannabinoid pharmacology is complex but supports the therapeutic potential of targeting the ECS. Third, we review the clinical evidence and discuss the future perspectives on how to bridge human and animal studies to develop cannabinoid-based therapies for each neurodegenerative disorder. Finally, we summarize the most relevant opportunities of cannabinoid pharmacology related to each disease and the multiple unexplored pathways in cannabinoid pharmacology that could be useful for the treatment of neurodegenerative diseases.

show abstract

Section: Clinical Evidence For the Therapeutic Potential Of Cannabinomentioning

confidence: 99%

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Aymerich

Aso

Abellanas

et al. 2018

Biochemical Pharmacology

View full text Add to dashboard Cite

show abstract

“…Two (20 and 22 subjects) found no side effects of medical cannabis consumption . The third, a telephone survey of 47 patients with Parkinson disease treated with medical cannabis (supported by Tikun‐Olam Ltd), concluded that the treatment improved PD symptoms . Five patients (10.6%) stopped cannabis treatment 3 to 12 months after initiating it.…”

Section: Central Nervous Systemmentioning

confidence: 99%

Medical cannabis: aligning use to evidence‐based medicine approach

Schleider

Abuhasira

Novack

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

During the past decade we have been witnessing a rise in medical cannabis use, yet the evidence for the safety and efficacy of the various cannabinoid compounds is scarce. The State of Israel has always been at the forefront of clinical and translational research in support of Evidence Based Medicine. With respect to cannabis Israel has created a medical and regulatory environment that enables clinical studies with cannabis which may lead to improved Evidence Based use of these compounds. This opinion paper discusses selected studies into the safety and effects of cannabis derived products.

show abstract

“…Epidemiological studies are also encouraging. A retrospective survey found an improvement of PD symptoms with medical cannabis in the initial stages of treatment, with no evidence of major adverse effects [49]. Another epidemiological study pointed to the possible effect of cannabidiol in improving the quality of life of PD patients without psychiatric comorbidities.…”

Section: Is There Enough Data Supporting Protective or Therapeutic Romentioning

confidence: 99%

“…Furthermore, Parkinsonism was also described as a consequence of heroin consumption, which is a depressor of the central nervous system [ 47 , 48 ]. Conversely, scientific data supports that other substances of abuse, such as some phytocannabinoids, which interact with the endocannabinoid system, may play a neuroprotective role in PD [ 49 , 50 , 51 , 52 , 53 , 54 , 55 ]. Interestingly, both neurotoxic and neuroprotective effects are described as the outcomes from different drugs of abuse consumption.…”

Section: Introductionmentioning

confidence: 99%

Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease

Ferreira

Almeida²,

Tenreiro

et al. 2020

Life

View full text Add to dashboard Cite

Parkinson’s Disease (PD) is currently the most rapid growing neurodegenerative disease and over the past generation, its global burden has more than doubled. The onset of PD can arise due to environmental, sporadic or genetic factors. Nevertheless, most PD cases have an unknown etiology. Chemicals, such as the anthropogenic pollutant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and amphetamine-type stimulants, have been associated with the onset of PD. Conversely, cannabinoids have been associated with the treatment of the symptoms’. PD and medical cannabis is currently under the spotlight, and research to find its benefits on PD is on-going worldwide. However, the described clinical applications and safety of pharmacotherapy with cannabis products are yet to be fully supported by scientific evidence. Furthermore, the novel psychoactive substances are currently a popular alternative to classical drugs of abuse, representing an unknown health hazard for young adults who may develop PD later in their lifetime. This review addresses the neurotoxic and neuroprotective impact of illicit substance consumption in PD, presenting clinical evidence and molecular and cellular mechanisms of this association. This research area is utterly important for contemporary society since illicit drugs’ legalization is under discussion which may have consequences both for the onset of PD and for the treatment of its symptoms.

show abstract

Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience

Cited by 63 publications

References 18 publications

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Medical cannabis: aligning use to evidence‐based medicine approach

Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease

Contact Info

Product

Resources

About